Efficacy and safety of anti-amyloid antibodies in Alzheimer’s disease: A comparison of conventional, Bayesian, and frequentist network meta-analyses
Danko Jeremic, Juan D Navarro-López, Lydia Jiménez-Díaz · FENS Forum 2024
Regulatory approvals of Aducanumab in the U.S. and Lecanemab (U.S and Japan) for the treatment of Alzheimer’s disease (AD) have launched the worldwide marketing campaign for these antibodies as one of the first drugs that not only alleviate the symptoms but also slow AD progression. Another potent anti-amyloid antibody, Donanemab, may gain approval in the near future, as it is reported to reduce amyloid burden and slow AD progression. However, the risk/benefit profile of these drugs remains uncertain, and there is no obvious scientific basis for choosing between different antibodies. Here, we
ePoster · Neuroscience